Table 3. Frequency of micronucleated polychromatic erythrocytes (MNPCE) and the percentage (%) of PCE/(PCE + NCE) in 500 erythrocytes in the bone morrow of Wistar rats treated with CMN SD, unmodified CMN, cDDP or their associations, analyzed in the micronucleus test.
| Treatments | Bone marrow erythrocytes | |
|---|---|---|
| MNPCEs/1000 PCEs | PCE/(PCE + NCE) ratio (%) | |
| Saline solution | 1.25 ± 0.78 | 52.6 ± 4.6 |
| GLA | 1.92 ± 1.1 | 54.7 ± 6.5 |
| CMN SD 5 | 2.25 ± 1.13 | 59.3 ± 6.2 |
| CMN SD 25 | 1.5 ± 0.82 | 53.4 ± 10.4 |
| CMN SD 50 | 2.42 ± 1.09 | 43.2 ± 6.0 |
| CMN 50 | 1.91 ± 1.27 | 55.7 ± 8.8 |
| cDDP | 13.25 ± 3.51* | 49.9 ± 5.6 |
| GLA + cDDP | 12.75 ± 3.32* | 44.8 ± 4.9 |
| CMN SD 5 + cDDP | 6.88 ± 1.77* # | 51.8 ± 5.9 |
| CMN SD 25 + cDDP | 5.33 ± 2.98* # | 53.9 ± 8.3 |
| CMN SD 50 + cDDP | 6.42 ± 3.12* # | 51.1 ± 3.0 |
| CMN 50 + cDDP | 7.08 ± 3.04* # | 51.0 ± 7.5 |
Saline solution or cDDP was administered intraperitoneally 30 min after the last gavage of CMN SD or unmodified CMN. cDDP: cisplatin (6 mg/kg b.w.); CMN: curcumin (5, 25 and 50 mg/kg b.w.); GLA: gelucire®50-13/aerosil®; SD: solid dispersion. The results represent the mean ± standard deviation for each group (six animals/group).
*
Significantly different from saline solution group.
#
Significantly different from cDDP group, assessed by ANOVA and Tukey’s post hoc test (p < 0.05).